SCHEMBL2804587

SCHEMBL2804587

O=C(O)N1CCc2c(O)cccc2C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.50
AKR1C1 Q04828 1/20 0.50
BCL2L1 Q07817 1/20 0.46
BAD Q92934 1/20 0.46
NOTUM Q6P988 1/20 0.44
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
ABHD6 Q9BV23 4/20 0.42
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
DRD2 P14416 2/20 0.41
DRD3 P35462 2/20 0.41
DRD1 P21728 1/20 0.41
DRD5 P21918 1/20 0.41
PPARG P37231 1/20 0.40
PPARD Q03181 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16269409 0.87 DRD1 (0.47) AKR1C3AKR1C1BCL2L1BADNOTUM
SCHEMBL6712189 0.85 NOTUM (0.63) AKR1C3AKR1C1BCL2L1BADNOTUM
SCHEMBL3163275 0.84 HPGD (0.53) AKR1C3AKR1C1MEN1KMT2ASMN1; SMN2
SCHEMBL16637906 0.84 TRAP1 (0.43) AKR1C3AKR1C1BCL2L1BADNOTUM
SCHEMBL30924716 0.82 NPC1 (0.47) NOTUMMEN1MAPTKMT2ATAAR1
SCHEMBL1550147 0.82 ABHD6 (0.60) AKR1C3NOTUMMEN1MAPTKMT2A
SCHEMBL16111044 0.82 AKR1C3 (0.51) AKR1C3NOTUMMEN1MAPTKMT2A
SCHEMBL8177222 0.81 ESR1 (0.56) AKR1C3AKR1C1BCL2L1BADABHD6
SCHEMBL1136171 0.81 RIPK1 (0.58) AKR1C3AKR1C1BCL2L1BADNOTUM
SCHEMBL17607348 0.80 RAC1 (0.38) NOTUMMEN1MAPTKMT2ATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1997023484-A1 NEW COMPOUNDS ASTRA AKTIEBOLAG (SE) 1997-07-03 WO claimed
US-11833162-B2 Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2023-12-05 US disclosed
EP-3700911-B1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2023-09-06 EP disclosed
CN-111511750-B Macrocyclic derivatives, process for their preparation and pharmaceutical compositions containing them 法国施维雅药厂 2023-06-13 CN disclosed
CN-115557968-A Fused tetracyclic compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2023-01-03 CN disclosed
EP-3700911-A1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Les Laboratoires Servier SAS (FR) 2020-09-02 EP disclosed
US-20200253993-A1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2020-08-13 US disclosed
CN-111511750-A Novel macrocyclic derivatives, process for their preparation and pharmaceutical compositions containing them 法国施维雅药厂 2020-08-07 CN disclosed
CN-105263924-B Cxcr7 receptor modulators 爱杜西亚制药有限公司 2018-10-19 CN disclosed
CN-105051037-B Sphingosine-1-phosphate receptor agonists, method for the preparation thereof and pharmaceutical compositions comprising the same as active agent LG化学株式会社 2018-05-18 CN disclosed
CN-102947285-B Sulfonamide derivatives as BCL-2-selective apoptosis inducers for the treatment of cancer and immune diseases ABBVIE (US) 2015-08-26 CN disclosed
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS INCYTE CORPORATION 2013-11-07 US disclosed
US-8481732-B2 Substituted heterocyclic compounds INCYTE CORPORATION (US) 2013-07-09 US disclosed
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS INCYTE CORPORATION (US) 2010-09-23 US disclosed
WO-2010108059-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR INCYTE CORPORATION (US) 2010-09-23 WO disclosed
EP-1483257-B1 QUINAZOLINE COMPOUNDS USEFUL IN THERAPY PFIZER LTD (GB) 2006-09-13 EP disclosed
US-6936619-B2 Cardiovascular disorders; antilipemic agents; sexual disorders PFIZER, INC. (US) 2005-08-30 US disclosed
US-20040029859-A1 Compounds useful in therapy PFIZER INC. 2004-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11833162-B2 Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same C1R, F12, RDX AKR1C3 33/4885AKR1C1 50/4885BCL2L1 3913/4885
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS HRH4, HRH2, HRH1 AKR1C3 577/4885AKR1C1 1068/4885BCL2L1 4766/4885
US-20040029859-A1 Compounds useful in therapy ADRA1D, HSD3B1, PTGER1 AKR1C3 181/4885AKR1C1 313/4885BCL2L1 1757/4885
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS HRH4, HRH2, HRH1 AKR1C3 603/4885AKR1C1 1199/4885BCL2L1 4779/4885
US-20200253993-A1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME C1R, RDX, F12 AKR1C3 48/4885AKR1C1 65/4885BCL2L1 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.